Key Drivers
- Cash Cushion
- Loss Burn
- Margin Collapse
AIAI Summary
RXRX is shifting from a speculative AI-platform story to a more credible proof-of-platform/proof-of-partnership setup, but it remains a neutral hold until collaboration wins and clinical progress translate into real revenue, since cash burn and weak commercialization are still the main risks despite runway into early 2028.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Loss Burn
- •Margin Collapse
RXRX has a strong cash-rich, low-debt balance sheet, but ongoing losses, negative free cash flow, and a sharp Q2 gross-margin deterioration make the stock financially risky despite ample liquidity.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •3.00 support
- •3.35 ceiling
RXRX has a mildly bullish last month trend, holding above $3.00 support but still capped by $3.30-$3.35 resistance after a quick pullback from $3.35.
Fast run-up to $3.35, then pullback to $3.16
Sentiment & News
Key News Insights:
- •Q2 Miss
- •Genentech Advance
- •Lower Burn
RXRX showed mixed near-term results as Q2 missed estimates and collaboration revenue weakened, but lower 2026 cash burn guidance, Genentech neuroscience progress, and upcoming pipeline milestones support the long-term story.
The news is mildly negative for near-term sentiment, but continued pipeline validation and improved cash discipline help sustain longer-term investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings